Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients

Primary Hyperoxaluria Clinical Trial

— PHOENIX  

Official title:

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00638703
• Other study ID #: OC3-DB-01
• Secondary ID: DB-01
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: March 12, 2008
• Last updated: May 7, 2013
• Start date: October 2007
• Est. completion date: October 2008

Study information

• Verified date: June 2011
• Source: OxThera
• Contact: n/a
• Is FDA regulated: No
• Health authority: European Union: European Medicines AgencyFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Federal Institute for Drugs and Medical DevicesNetherlands: The Central Committee on Research Involving Human Subjects (CCMO)United Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: October 2008
• Est. primary completion date: September 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 5 Years and older

Eligibility

Inclusion Criteria:

1. The subject (or legally acceptable representative) must give written informed consent (and assent for subjects = 12 years or country specific age as appropriate). For subjects less than 18 years of age, parent or guardian will provide informed consent and the subject will provide witnessed verbal assent

2. Male or female subjects = 5 years of age

3. Urinary oxalate excretion of > 1.0 mmol/1.73m2/day at Baseline

4. Documentation of diagnosis of PH I or PH II by any one of the following:

1. Liver biopsy confirmation of deficient liver specific peroxisomal alanine-glyoxylate aminotransferase, (AGT) or mislocalization of AGT from peroxisomes to mitochondria (PH I) or deficient glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) activity (PH II)

2. Homozygosity or compound heterozygosity for a known mutation in the causative genes for PH I and PH II

3. Increased glycolate excretion for PH I or increased L-glycerate excretion for PH II

5. Subjects receiving pyridoxine must be receiving a stable dose for at least 3 months prior to entry in to the study and must remain on the stable dose during the study. Other (non-pyridoxine naïve) subjects (e.g. Pyridoxine non-responder: <30% reduction of the urine oxalate levels) not receiving pyridoxine at study entry must be willing to refrain from initiating pyridoxine during study participation. Note: There will be no pyridoxine-naïve subjects enrolled in the study.

6. Renal function defined as an estimated GFR = 50 ml/min normalized to 1.73m2 body surface area

Exclusion Criteria:

1. Pregnant, lactating, or actively menstruating women and women of child-bearing potential who are not using adequate contraceptive precautions. Sexually active females, unless surgically sterile or at least 2 years post-menopausal, must be using a highly effective contraception (including oral, transdermal, injectable, or implanted contraceptives, IUD, abstinence, use of a condom by the sexual partner, or sterile sexual partner) for 30 days prior to the first dose of OxabactTM and must agree to continue using such precautions during the clinical study.

Note: A highly effective method of birth control is defined as one that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomised partner.

2. Positive serum pregnancy test.

3. Participation in any study of an investigational product, biologic, device, or other agent within 30 days prior to randomization or not willing to forego other forms of investigational treatment during this study.

4. Subjects on hemodialysis or peritoneal dialysis.

5. Subjects who have undergone transplantation (solid organ or bone marrow).

6. Chronic gastrointestinal disease associated with enteric hyperoxaluria, e.g. history of inflammatory bowel disease, colostomy. Note: For clarity, existence of Secondary Hyperoxaluria (e.g. with cystic fibrosis, chronic inflammatory bowel diseases, short bowel syndrome and/or deficiency of intestinal oxalate-degrading bacteria is included (as an exclusion criteria).

7. Current systemic (oral, IM, IV) antibiotic use or received systemic antibiotics within 14 days of study enrolment.

8. History of chronic, recurrent infections requiring >2 courses of antibiotics in the past 6 months.

9. History of malignancy except for basal or squamous cell skin cancer that has been excised.

10. Unable to collect 24-hour urine samples or follow other study procedures.

11. Subjects who cannot swallow a size 2 capsule.

12. Presence of a medical condition that the Principal Investigator considers likely to make the subject susceptible to adverse effect of study treatment or unable to follow study procedures.

13. Subjects who require immune suppressive therapy (including prednisone of > 10mg daily for more than 2 weeks).

14. Subjects from correctional facilities or asylums.

15. Subjects who are mentally handicapped.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hyperoxaluria, Primary
• Primary Hyperoxaluria

Intervention

Biological:
• Oxalobacter formigenes
NLT (not less than) 10^7 CFU Oxalobacter formigenes twice daily for 24 weeks

Drug:
• Placebo
placebo

Locations

Country	Name	City	State
United States	Mayo Clinic (Department of Pediatric Nephrology)	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
OxThera

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in urinary oxalate Percentage change in urinary oxalate (expressed as mmole/1.73m2 /day) from Baseline to Week 24		24 weeks	No
Secondary	Percentage of subjects who are responders at Week 24 where response is defined as a 20% or greater reduction from Baseline urinary oxalate to Week 24		24 weeks	No
Secondary	Percentage change in urinary oxalate (expressed as molar oxalate to creatinine ratio) from Baseline to Week 24		24 weeks	No
Secondary	Percentage change in urinary oxalate (expressed as mmole/1.73m2/day and as molar oxalate to creatinine ratio) from Baseline to Week 12		12 weeks	No
Secondary	Percentage change in urinary oxalate (expressed as mmole/1.73m2/day and as molar oxalate to creatinine ratio) from Baseline to average of Weeks 12 and 24		12 and 24 weeks	No
Secondary	Frequency of AEs and SAEs		over 24 weeks	Yes
Secondary	Laborator safety data		12 and 24 weeks	Yes